Biotech news
Americas
Innovations in life sciences have dramatically advanced the quality of US healthcare, while diagnostic tests and drug therapies that once seemed beyond our grasp have now become standard. 21 September 2020
Biotech
In a blow for biotechnology company, Biogen, a US federal judge has ruled that its lone surviving patent on multiple-sclerosis drug Tecfidera should remain invalid because the matter had already been resolved by another court. 21 September 2020
Americas
Merck & Co is set to make a $1 billion investment in biotech company Seattle Genetics, as the companies collaborate to develop and sell Seattle Genetics’ cancer therapy, ladiratuzumab vedotin. 16 September 2020
Biotech
In the fast-paced environment of life sciences, the need for the IP sector to take full advantage of potential and emerging innovations is paramount, as a LSPN Connect session discovered. 14 September 2020
Americas
Human embryos whose genomes have been edited should not be used to create a pregnancy until it is certain that changes can be made without introducing undesired changes, according to a new report by an influential panel. 10 September 2020
Americas
A US Department of Health and Human Services agency will investigate whether Moderna disclosed information on government funding in patent applications relating to its COVID-19 vaccine. 8 September 2020
Biotech
Biologics are playing an increasingly important role in healthcare, but for corporate patent counsel, the differences in rules between the US and Europe are a real cause for concern. 4 September 2020
Americas
California-based molecular diagnostics company CareDx and Stanford University have dropped their patent infringement suit against Tai Diagnostics, nearly five months after filing the complaint. 3 September 2020
Asia
As AI becomes a crucial weapon in the battle against the global pandemic, companies in the field need to ensure that their valuable IP is protected, as Mao Xiao Hong and Danny Yap of IPOS International explain. 1 September 2020
Biotech
In an LSPN Connect session, Millipore’s senior corporate patent counsel, Ben Sodey, and head of legal and IP at Arbor, Kelly Morgan, shared their insights on the latest developments in this area of gene editing technology. 21 August 2020